Aptevo Therapeutics (APVO) Stock

SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No.

Powered by Aptevo's proprietary ADAPTIR-FLEX®platform, antibody innovation targeting difficult-to-treat cancers SEATTLE, WA / ACCESSWIRE / December 4, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced additional details about the Company's preclinical bispecific antibody, APVO442, differentiated to target prostate cancer with enhanced precision and minimized safety risk. APVO442 is the first molecule developed using Aptevo's cutting-edge ADAPTIR-FLEX platform, which is driving innovation in antibody engineering for complex disease management.

Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment SEATTLE, WA / ACCESSWIRE / November 22, 2024 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, provided additional details about its robust oncology pipeline which is poised to potentially address some of the most challenging and aggressive forms of cancer in both blood and solid tumors. As bispecific antibodies gain prominence for their revolutionary therapeutic potential and expanding market opportunities, Aptevo's differentiated platforms (ADAPTIR® and ADAPTIR-FLEX®) and promising clinical results across two clinical programs (mipletamig and ALG.APV-527), together with preclinical assets (APVO711, APVO603 and APVO442) are demonstrating how bispecifics rationally differentiated for safety and targeted efficacy may impact the future of cancer care.

Company Achieves Milestones in Both Clinical Programs Initiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial Results Presented Interim Data from ALG.APV-527 Phase 1 Trial in Multiple Solid Tumors at the European Society for Medical Oncology Congress Additional Favorable Data to be Presented at the Society for Immunotherapy of Cancer Conference on November 8th Raises $5.75 Million in the Quarter SEATTLE, WA / ACCESSWIRE / November 7, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ending September 30, 2024 and provided a business update. Business Highlights Aptevo met multiple clinical milestones in the third quarter, including: Based on positive safety, tolerability efficacy and durability data in its completed dose escalation trial, Aptevo Initiated the mipletamig Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate the compound in combination with standard of care venetoclax + azacitidine in frontline patients with acute myeloid leukemia (AML).

Aptevo Therapeutics (APVO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended March 31, 2024 and provided a business update. "After the successful completion of our APVO436 dose expansion trial, where we saw a 91% clinical benefit rate and an excellent safety, tolerability and duration of remission profile, we worked in the second quarter to finalize plans for the launch of the first part of our Phase 1b/2 trial, a dose optimization study, continuing evaluation of APVO436 in combination with venetoclax and azacitidine for the treatment of Acute Myeloid Leukemia (AML) in frontline patients.

SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 5,339,806 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 10,679,612 shares of its common stock (the "Common Warrants") at a purchase price of $0.515 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock.

Aptevo's stock drops following the issuance of additional shares at a discounted price, resulting in a significant dilution of existing shareholders.

Aptevo Therapeutics (NASDAQ: APVO) shares are declining today following the announcement of a public offering in which the company will sell 3.4 million shares of APVO stock at $1.35 per share.